1. Home
  2. BRBS vs SABS Comparison

BRBS vs SABS Comparison

Compare BRBS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Ridge Bankshares Inc.

BRBS

Blue Ridge Bankshares Inc.

HOLD

Current Price

$3.46

Market Cap

322.8M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.50

Market Cap

280.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRBS
SABS
Founded
1893
2014
Country
United States
United States
Employees
N/A
86
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
322.8M
280.2M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
BRBS
SABS
Price
$3.46
$3.50
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
363.4K
730.2K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
24.78%
N/A
EPS Growth
135.48
N/A
EPS
0.01
N/A
Revenue
$111,284,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$339.00
N/A
Revenue Growth
123.99
N/A
52 Week Low
$3.23
$1.85
52 Week High
$4.79
$5.15

Technical Indicators

Market Signals
Indicator
BRBS
SABS
Relative Strength Index (RSI) 50.60 41.58
Support Level $3.41 $3.42
Resistance Level $3.53 $4.10
Average True Range (ATR) 0.07 0.20
MACD -0.01 -0.03
Stochastic Oscillator 56.25 6.36

Price Performance

Historical Comparison
BRBS
SABS

About BRBS Blue Ridge Bankshares Inc.

Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: